Clinical Trials Logo
  1. Home
  2. Esophageal Carcinoma
  3. NCT01691625
  4. Details
NCT01691625 Clinical Trial

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

Esophageal Carcinoma Clinical Trial

Official title:
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01691625
Other study ID # JR-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2012
Est. completion date December 2021

Study information
Verified date February 2024
Source Capital Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to show if the adoptive cellular therapy with autologous dendritic cells and cytokine-induced killer cells (CIK) combined with concurrent chemoradiation could improve the quality of life of the patients with locally advanced esophageal cancer, compared with concurrent chemoradiation only.

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date December 2021
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - cytologically or histologically confirmed locally advanced esophageal carcinoma - Age: > 18 - Karnofsky performance status = 70 - At least one measurable tumor lesions according to the RECIST criteria. - Normal functions of heart, lung, liver, kidney and bone marrow - Blood exams qualified for chemotherapy, which included hemoglobulin =9 g/dl, neutrophil =1.5×109/L and platelet (PLT) =100×109/L, creatinine =1.5 UNL - Informed consent signed Exclusion Criteria: - Patients with metastatic disease in the central nervous system (CNS). - Patients who are pregnant or nursing. - Patients with poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable - Patients with contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis - coexisted morbidities that investigators believed not suitable for chemoradiation

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• concurrent chemoradiotherapy plus DC-CIK immunotherapy
Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator. Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation. DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period.
• Concurrent chemoradiation only
Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator. Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.

Locations
Country Name City State
China Capital Medical University Cancer Center Beijing Beijing

Sponsors (1)
Lead Sponsor Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Other Immunological assessment Cytokine secretion and T cell populations are assessed. baseline, months 1, 3, 6 and 12
Primary the quality of life initial assessment, months 1, 3, 6 and 12
Secondary progression-free survival 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Recruiting NCT02355249 - Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer Phase 3
Not yet recruiting NCT05937438 - Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma Phase 1/Phase 2
Recruiting NCT05777707 - Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma Phase 1/Phase 2
Recruiting NCT02527057 - Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer N/A
Withdrawn NCT00636298 - Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy Phase 2
Recruiting NCT06009705 - Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
Recruiting NCT04652180 - Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy . N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Withdrawn NCT03220009 - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Phase 2
Recruiting NCT06199895 - Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Phase 2
Completed NCT00590031 - Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. Phase 2
Active, not recruiting NCT00176800 - Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma Phase 2
Completed NCT03099382 - Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer Phase 3
Active, not recruiting NCT04607590 - Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
Recruiting NCT00991094 - Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Completed NCT01855854 - Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Phase 2
Not yet recruiting NCT06067438 - Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2